Genprex, Inc. (GNPX)
NASDAQ: GNPX · IEX Real-Time Price · USD
1.885
-0.025 (-1.31%)
Jul 22, 2024, 11:12 AM EDT - Market open
Genprex Employees
Genprex had 26 employees as of December 31, 2023. The number of employees decreased by 2 or -7.14% compared to the previous year.
Employees
26
Change (1Y)
-2
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$1,062,560
Market Cap
3.96M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| China Pharma Holdings | 231 |
| OpGen | 100 |
| iSpecimen | 53 |
| Sintx Technologies | 43 |
| CERo Therapeutics Holdings | 9 |
| Palisade Bio | 9 |
| Allarity Therapeutics | 6 |
| MyMD Pharmaceuticals | 6 |
GNPX News
- 25 days ago - Genprex Issues Stockholder Letter and Provides 2024 Corporate Update - PRNewsWire
- 7 weeks ago - Genprex to Present at the 2024 BIO International Convention - PRNewsWire
- 2 months ago - Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PRNewsWire
- 2 months ago - Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors - PRNewsWire
- 2 months ago - Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner - PRNewsWire
- 2 months ago - Genprex to Present and Participate at Upcoming May Investor and Industry Conferences - PRNewsWire
- 3 months ago - Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting - PRNewsWire
- 3 months ago - Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PRNewsWire